Nat Commun:缺血坏死心肌交感神经支配或能重建

2015-02-04 佚名 生物谷

最近Case Western Reserve University的科学家们意外发现用于恢复脊髓功能的化合物可能有另外一个神奇的作用-阻止心肌缺血坏死后致命性心律失常的发生。这种特殊的物质能进入心肌瘢痕促进心脏神经的再生。这个研究发表在最新一期的Nature Communications杂志上。 这种化合物名为西格玛内肽(intracellular sigma peptide, ISP),一

最近Case Western Reserve University的科学家们意外发现用于恢复脊髓功能的化合物可能有另外一个神奇的作用-阻止心肌缺血坏死后致命性心律失常的发生。这种特殊的物质能进入心肌瘢痕促进心脏神经的再生。这个研究发表在最新一期的Nature Communications杂志上。

这种化合物名为西格玛内肽(intracellular sigma peptide, ISP),一直被Case Western Reserve University神经科学的Silver教授用于脊髓修复的研究。他与同事从事心脏病研究的Habecker教授交流时发现心肌“疤痕”与脊髓损伤有共同之处-脊髓损伤和有神经损伤的心肌都存在一种蛋白多糖的分子,这种分子在机体受损后参与瘢痕的形成,但是在形成同时神经被"吞噬"。由于ISP对修复脊髓损伤有一定的作用,于是Habecker教授领导的研究小组开始在心脏瘢痕上进行实验。

研究人员在小鼠身上模拟了心脏病发作的过程,然后用ISP,盐水和另外一种非治疗性的肽(对照)给予小鼠治疗。结果发现两周后所有接受ISP治疗的小鼠整个左心室的心脏交感神经功能恢复到正常水平,包括心肌缺血坏死的区域。而且在这些小鼠身上未检测到任何心律失常表现。而其他两个对照组的小鼠缺血坏死的心肌却正常的交感神经活动,出现了心律失常。

早有研究发现交感神经与心脏骤停或者心律失常有密切的关系。最近的临床研究已经确认去交感神经可作为心律失常易感性增加的预测指标。而据统计,有7%到10%的人在心脏病发作后六个月内死于心律失常。所以ISP在缺血心肌上重建交感神经支配的作用是一个十分重大的发现,将来可用于心脏病后的基础预防性治疗。

原始出处

Gardner RT1, Wang L2, Lang BT3, Cregg JM3, Dunbar CL1, Woodward WR4, Silver J3, Ripplinger CM2, Habecker BA1.Targeting protein tyrosine phosphatase σ after myocardial infarction restores cardiac sympathetic innervation and prevents arrhythmias.Nat Commun. 2015 Feb 2

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1880485, encodeId=be53188048521, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Nov 12 23:12:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805944, encodeId=51e318059443f, content=<a href='/topic/show?id=99fbe93492d' target=_blank style='color:#2F92EE;'>#缺血坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79349, encryptionId=99fbe93492d, topicName=缺血坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Dec 10 01:12:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086762, encodeId=ac992086e6226, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 12 20:12:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16200, encodeId=17c01620062, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 00:54:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362784, encodeId=7d661362e8468, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Fri Feb 06 00:12:00 CST 2015, time=2015-02-06, status=1, ipAttribution=)]
    2015-11-12 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1880485, encodeId=be53188048521, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Nov 12 23:12:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805944, encodeId=51e318059443f, content=<a href='/topic/show?id=99fbe93492d' target=_blank style='color:#2F92EE;'>#缺血坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79349, encryptionId=99fbe93492d, topicName=缺血坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Dec 10 01:12:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086762, encodeId=ac992086e6226, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 12 20:12:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16200, encodeId=17c01620062, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 00:54:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362784, encodeId=7d661362e8468, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Fri Feb 06 00:12:00 CST 2015, time=2015-02-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1880485, encodeId=be53188048521, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Nov 12 23:12:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805944, encodeId=51e318059443f, content=<a href='/topic/show?id=99fbe93492d' target=_blank style='color:#2F92EE;'>#缺血坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79349, encryptionId=99fbe93492d, topicName=缺血坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Dec 10 01:12:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086762, encodeId=ac992086e6226, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 12 20:12:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16200, encodeId=17c01620062, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 00:54:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362784, encodeId=7d661362e8468, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Fri Feb 06 00:12:00 CST 2015, time=2015-02-06, status=1, ipAttribution=)]
    2015-09-12 liuli5079
  4. [GetPortalCommentsPageByObjectIdResponse(id=1880485, encodeId=be53188048521, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Nov 12 23:12:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805944, encodeId=51e318059443f, content=<a href='/topic/show?id=99fbe93492d' target=_blank style='color:#2F92EE;'>#缺血坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79349, encryptionId=99fbe93492d, topicName=缺血坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Dec 10 01:12:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086762, encodeId=ac992086e6226, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 12 20:12:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16200, encodeId=17c01620062, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 00:54:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362784, encodeId=7d661362e8468, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Fri Feb 06 00:12:00 CST 2015, time=2015-02-06, status=1, ipAttribution=)]
    2015-02-17 chinayinhan

    已阅

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1880485, encodeId=be53188048521, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Nov 12 23:12:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805944, encodeId=51e318059443f, content=<a href='/topic/show?id=99fbe93492d' target=_blank style='color:#2F92EE;'>#缺血坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79349, encryptionId=99fbe93492d, topicName=缺血坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Dec 10 01:12:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086762, encodeId=ac992086e6226, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 12 20:12:00 CST 2015, time=2015-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16200, encodeId=17c01620062, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 00:54:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362784, encodeId=7d661362e8468, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Fri Feb 06 00:12:00 CST 2015, time=2015-02-06, status=1, ipAttribution=)]
    2015-02-06 millore

相关资讯

JACC Cardiovasc Interv:解剖学负荷预测结果优于缺血负荷(COURAGE亚组研究)

根据最近发表于JACC的一项COURAGE亚组研究显示,解剖学负荷对于采用最佳药物治疗(有或无血运重建治疗)的稳定型冠心病患者是一个良好的预测结果,而非缺血性负荷。 首席研究员G.B.约翰•曼奇尼博士指出,在这些患者中使用各种药物治疗和血管形成术,结果显示缺血基线水平并不能预测的风险,而低射血分数或冠状动脉疾病的量在整个试验中该作用未间断。 但是除药物治疗外,无论危险分层措施单独或组合使用均有

Stroke:治疗急性局灶性缺血性脑卒中的新方法

 一项最新研究表明,在早期入院且年龄大于70岁或患有轻度中风的患者中,一种可增加脑血流量的新型导管治疗(NeuroFlo)法对其全因死亡率有效,但是否适合临床普及,尚有待进一步的确认。该项研究成果已在线发表于《卒中》期刊网站。 目前,接受治疗的急性局部缺血性脑卒中患者不足5%,而且其对额外可选择的疗法尚有需求。一种可增加脑血流量的新型导管治疗(NeuroFlo)接受了长达14小时的检

张运:冠心病发病机制的“太阳系”新概念--关注缺血而非狭窄

一、“金标准”的由来目前临床上,无论诊断或治疗,均严格遵循“金标准”——冠状动脉造影的结果。冠状动脉造影显示患者血管直径狭窄≥50%,即诊断为冠心病。即使包括心电图、超声心动图和核磁等在内的其他诊断技术检测结果呈阳性,只要造影显示狭窄<50%,就认定其他结果为假阳性;反过来,其他检测结果呈阴性,只要造影显示为阳性,就认定其他结果为假阴性。而治疗标准为:≥70%的狭窄实施介入治疗,<70%则不进

PNAS:血管内皮细胞“Gab1-PKA-eNOS”信号转导通路在缺血性血管新生过程中起关键作用

北京大学分子医学研究所(IMM)罗金才研究组发现,血管内皮细胞“Gab1-PKA-eNOS”信号转导通路在缺血性血管新生过程中起关键作用。 附图:Gab1基因敲除导致小鼠缺血性血管新生、侧枝循环建立出现缺陷(图示上半部分),主要是由于血管内皮细胞管状结构形成的信号调控通路出现障碍而引起的(图示下半部分)。 血管新生是心脑、肌肉等组织器官缺血缺氧后进行自身修复的重要环节,在促进血液循环、防止组织

NEJM:手指缺血性坏死一例

患者,女,69岁,双手手指呈缺血性坏死症状,症状持续有2月(图A和图B)。一年前,患者曾患过肖格伦综合征,并且发展为雷诺综合征,具疼痛感。 A B 硝苯地平和局部硝酸甘油治疗后不改善症状。患者不抽烟,有巨球蛋白血症家族病史。血液检测提示冷球蛋白阳性,血清蛋白电泳结合免疫固定提示在分子量为345mg/dL的地方有一单克隆IgM抗体峰伴随kappa轻链限制性。乙肝

新型溶栓药物desmoteplase出现转机 能改善缺血性卒中的预后

今年6月,灵北(Lundbeck)新一代溶栓药物去氨普酶(desmoteplase)首个III期研究(DIAS-3)失败,为该药临床项目的推进蒙上了阴影。此前,业界曾对该药寄予厚望,FDA也已授予该药快车道地位。近日,desmoteplase临床项目似乎迎来转机,采用新的分析方法发现,desmoteplase与较好的功能预后相关。新分析数据同时表明,检测早期缺血性损伤时,与电脑断层扫描(CT)相比